[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fayoum University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":603},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,43,74,100,123,157,183,216,240,264,286,307,337,357,378,398,418,439,462,479,504,526,546,567,584],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100643839","phase-4-clinical-and-radiographic-evaluation-of-doxycycline-and-atorvastatin-loaded-chitosan-nanoparticles-as-an-adjunctive-to-scaling-and-root-planning-in-the-management-of-chronic-periodontitis-a-randomized-controlled-clinical-trial-100643839",false,"NCT07634341","Clinical and Radiographic Evaluation of Doxycycline and Atorvastatin Loaded Chitosan Nanoparticles as an Adjunctive to Scaling and Root Planning in the Management of Chronic Periodontitis. A Randomized Controlled Clinical Trial.","Clinical and Radiographic Evaluation of Doxycycline and Atorvastatin Loaded Chitosan Nanoparticles as an Adjunctive to Scaling and Root Planning in the Management of Chronic Periodontitis: A Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* In order for patients to be considered in the study, they must meet the following criteria: 1) they should have stage II and stage III periodontitis 2) Patients' age range equal or more than 25 years old .\n\nExclusion Criteria:\n\n\\- Patients with any systemic condition that may affect periodontal health and bone formation, such as; those who are pregnant, nursing, or postmenopausal women; DM, CVD, metabolic syndrome, osteoporosis, AIDS and chronic alcoholism .\n\n2\\) Patients having local factors that may aggravate and predispose for periodontal diseases such as; orthodontic and prosthetic appliances and parafunctional habits 3)smoking (A patient was classified as a current smoker if they smoked more than 10 cigarettes per day regularly for a minimum period of 5 years) 4) Individuals on systemic drug affecting metabolic bone diseases , Medications taken for the treatment of arthritis and psychotropic and epileptic disorders, as well as anticoagulants, antacids, bisphosphonates, corticosteroids, and antineoplastic drugs, can profoundly affect bone metabolism","ALL","25 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Chronic periodontitis is one of the most prevalent inflammatory diseases affecting the tooth-supporting structures and is characterized by progressive clinical attachment loss and alveolar bone resorption resulting from a complex interaction between pathogenic microorganisms and the host inflammatory and immune responses. If left untreated, the disease may ultimately lead to tooth loss and negatively affect oral health and quality of life.\n\nScaling and root planing (SRP) is considered the gold-standard non-surgical treatment for chronic periodontitis. It aims to remove dental plaque and calculus deposits and reduce the subgingival bacterial load. Although SRP has demonstrated significant clinical benefits, its effectiveness may be limited in certain situations, particularly in deep periodontal pockets and anatomically complex areas that are difficult to access. Therefore, adjunctive therapeutic approaches have been investigated to enhance treatment outcomes and improve long-term periodontal stability.\n\nIn recent years, local drug delivery systems have gained considerable attention in periodontal therapy due to their ability to provide high therapeutic concentrations directly at the site of infection while minimizing systemic adverse effects. Chitosan has emerged as a promising biomaterial for this purpose because of its excellent biocompatibility, biodegradability, antimicrobial properties, and its ability to form nanoparticles capable of sustained and controlled drug release within periodontal pockets.\n\nDoxycycline is widely used in periodontal treatment because of its antimicrobial activity against periodontal pathogens as well as its ability to inhibit matrix metalloproteinases (MMPs), which play a key role in connective tissue destruction and alveolar bone loss. Furthermore, recent studies have demonstrated that atorvastatin, beyond its well-known lipid-lowering effects, possesses anti-inflammatory, immunomodulatory, and osteogenic properties that may contribute to periodontal tissue regeneration and improved clinical outcomes.\n\nThe research problem arises from the limited effectiveness of scaling and root planing alone in some cases of chronic periodontitis and the need for innovative adjunctive therapies that combine antimicrobial, anti-inflammatory, and bone regenerative effects. Therefore, evaluating the therapeutic potential of chitosan nanoparticles loaded with doxycycline and atorvastatin may provide a novel and effective approach for periodontal treatment.\n\nThe aim of this study is to clinically and radiographically evaluate the effectiveness of chitosan nanoparticles loaded with doxycycline and atorvastatin as an adjunct to scaling and root planing in patients with chronic periodontitis. Clinical outcomes, including probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), and bleeding on probing (BOP), as well as radiographic changes in alveolar bone levels, will be assessed and compared with conventional treatment outcomes. The findings of this study may contribute to the development of a more effective and biologically targeted therapeutic strategy for the management of chronic periodontitis.",[27],"Chronic Periodontitis",[29],"deep periodontal pocket local drug Doxycycline Atorvastatin","NOT_YET_RECRUITING","2026-06-03",{"date":33,"type":34},"2026-06-08","ACTUAL",{"date":36,"type":21},"2026-06",{"date":38,"type":21},"2027-12",{"name":40,"class":41},"Fayoum University","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100627156","comparative-evaluation-of-xenograft-alone-and-sticky-bone-in-sinus-lift-with-concurrent-implant-placement-100627156","NCT07444970","Comparative Evaluation of Xenograft Alone and Sticky Bone in Sinus Lift With Concurrent Implant Placement","Comparative Evaluation of Xenograft Alone and Sticky Bone in Sinus Lift With Concurrent Implant Placement: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Patients presenting with residual bone height of less than 5 millimeters in the posterior maxilla requiring sinus floor elevation for dental implant placement.\n* Good oral hygiene status with absence of active periodontal disease.\n* Medically fit patients with no systemic conditions contraindicating oral surgical procedures.\n* Non-smokers.\n* Absence of acute or chronic maxillary sinusitis.\n\nExclusion Criteria:\n\n* Presence of uncontrolled systemic diseases (e.g., uncontrolled diabetes mellitus or severe cardiovascular diseases).\n* Immunocompromised patients.\n* History of radiation therapy to the head and neck region.\n* History of sinus surgery or sinus pathology that may interfere with sinus floor elevation procedures.\n* Presence of active infection or inflammation at the intended surgical site.\n* Use of medications known to affect bone metabolism or healing, such as bisphosphonates or long-term corticosteroid therapy.","18 Years",{"count":52,"type":21},18,[54],"NA","Introduction \\& Background:\n\nModern dental implantology offers solutions for patients with edentulism in the maxillary arch, where sinus pneumatization and alveolar ridge atrophy are common conditions. This often requires sinus floor elevation and bone grafting prior to implant placement. Techniques such as the lateral window approach and osteotome-mediated sinus floor elevation aim to achieve sufficient vertical bone height for successful implant placement.\n\nAutogenous bone grafts have long been considered the gold standard; however, their use is associated with limitations including donor site morbidity and graft volume loss, which has encouraged the exploration of alternative grafting materials. Sticky bone is a term used in oral surgery and implantology to describe a cohesive, moldable, and adhesive bone graft material prepared by combining particulate bone graft material (xenograft) with biological additives such as Platelet-Rich Plasma (PRP) or Platelet-Rich Fibrin (PRF).\n\nPlatelet-Rich Fibrin (PRF), which is used in the present study, is an autologous leukocyte and platelet-rich fibrin matrix containing cytokines, platelets, and stem cells. PRF acts as a biodegradable scaffold that promotes microvascularization and guides epithelial cell migration. In addition, PRF may serve as a carrier for regenerative cells and allows sustained release of growth factors over a period ranging from one to four weeks, thereby enhancing the wound healing environment.\n\nObjectives:\n\nThe study aims to assess the clinical efficacy of sticky bone as a bone graft material in sinus lift procedures compared with conventional xenograft materials.\n\nMethods:\n\nA randomized clinical trial will be conducted comparing two groups: one receiving sticky bone with simultaneous implant placement and another receiving xenograft with implant placement. Preoperative assessment will include Cone Beam Computed Tomography (CBCT) imaging, followed by postoperative monitoring to evaluate bone height and implant stability.\n\nStudy Design:\n\nPatients fulfilling the inclusion and exclusion criteria will be recruited from the dental clinic. Written informed consent will be obtained from all participants after explanation of study procedures, potential risks, and expected benefits. Eligible patients will be randomly allocated into two equal groups using a computer-generated randomization program: Group 1 (Sticky Bone group) and Group 2 (Xenograft group).\n\nStatistical Analysis:\n\nSample size calculation was performed using G\\*Power software version 3.1.9.7. The statistical test family selected was the t-test. Based on data from a previous study, a total of 16 participants were required to achieve a study power of 80% with a significance level (alpha) of 0.05. To compensate for potential dropouts, the total sample size was increased to 18 participants (9 patients per group).",[57,58,59],"Sinus Lifting","Dental Implant","Sticky Bone",[61,62,63,64,65],"Dental implants","sticky bone","bone graft","sinus lift","PRF","2026-05-21",{"date":68,"type":34},"2026-05-26",{"date":70,"type":21},"2026-06-01",{"date":72,"type":21},"2027-04-01",{"name":40,"class":41},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":50,"enrollmentInfo":80,"targetDuration":82,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100634866","effect-of-positive-end-expiratory-pressure-titration-on-venous-excess-ultrasound-score-and-renal-outcomes-in-patients-with-acute-respiratory-distress-syndrome-100634866","NCT07545252","Effect of Positive End-Expiratory Pressure Titration on Venous Excess Ultrasound Score and Renal Outcomes in Patients With Acute Respiratory Distress Syndrome","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosis of ARDS according to the Berlin criteria.\n* Invasive mechanical ventilation ≥24 hours.\n* Requirement of PEEP ≥5 cmH₂O.\n\nExclusion Criteria:\n\n* Known end-stage renal disease on chronic dialysis.\n* History of renal transplantation.\n* Pregnancy.\n* Known severe tricuspid regurgitation.\n* Chronic liver disease with portal hypertension.\n* Poor ultrasound window precluding adequate venous Doppler assessment.",{"count":81,"type":21},40,"3 Days","OBSERVATIONAL","This study is a prospective observational cohort study conducted planned to include 40 patients with ARDS to assess the effect of different levels of PEEP titration on VExUS score and renal outcomes in patients with Acute Respiratory Distress Syndrome.",[86],"Acute Respiratory Distress Syndrome (ARDS)",[88,89,90,91],"ARDS","mechanically ventilatuon","PEEP Titration","VExUS","2026-04-16",{"date":94,"type":34},"2026-04-22",{"date":96,"type":21},"2026-04-12",{"date":98,"type":21},"2026-10-12",{"name":40,"class":41},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100634202","phase-2-metformin-and-alveolar-cleft-100634202","NCT07536620","Metformin and Alveolar Cleft","Does the Addition of Metformin to Autogenous Bone Graft Improve the Bone Quality After Alveolar Cleft Reconstruction? A Randomized Clinical Trial","Inclusion criteria:\n\n* Patients with no syndromic unilateral alveolar cleft.\n* Patients' ages observed between 8 and 12 years.\n\nExclusion Criteria:\n\n* Syndromic cases will be excluded\n* Previous operated cases","8 Years","12 Years",{"count":5,"type":21},[111],"PHASE2","* Completed medical history will take for all patients. All patients' guardians were informed about the procedure, the possible postoperative complications, and requested to sign an informed consent that was translated into Arabic language.\n* Patients were randomly divided into two equal groups by means of sealed envelopes:\n\n  * Group A ( study group) 18 patients who received a combination of illiac cancellous bone graft and 2ml of 1% metformin gel (20mg of metformin with 2% hydroxymethyl cellulose)\n  * Group B (control group): 18 patients who received illiac cancellous bone graft and 2 ml placebo gel (2% hydroxymethyl cellulose) Preparation of the Donor Site (Anterior Iliac Crest) and Harvesting of the Bone Graft\n  * A standard incision will be done to expose the anterior iliac crest. The cancellous bone graft will be harvested using 8 mm diameter trephine bur (KLS Martin, city, Germany). The graft will be harvested by molt and surgical curettes. The wound was then closed in the usual manner.\n  * For group A, the patients will receive iliac bone graft mixed with metformin gel and packed into the defect While in group B, the iliac bone graft will be mixed with placebo gel and packed into the defect.\n  * The labial flap was then approximated to the palatal one and sutured over the cleft area beginning with a horizontal mattress suture followed by multiple interrupted sutures to completely cover the grafted area",[114],"Alveolar Cleft","2026-04-11",{"date":117,"type":34},"2026-04-17",{"date":119,"type":21},"2026-05-01",{"date":121,"type":21},"2027-05-30",{"name":40,"class":41},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":130,"sex":17,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":144,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":42},"100626441","efficacy-of-ultrasound-guided-greater-auricular-nerve-block-in-preventing-postoperative-emergence-agitation-in-pediatric-patients-undergoing-microscopic-middle-ear-surgery-100626441","NCT07435675","Efficacy of Ultrasound-guided Greater Auricular Nerve Block in Preventing Postoperative Emergence Agitation in Pediatric Patients Undergoing Microscopic Middle Ear Surgery.","Efficacy of Ultrasound-guided Greater Auricular Nerve Block in Preventing Postoperative Emergence Agitation in Pediatric Patients Undergoing Microscopic Middle Ear Surgery: A PROSPECTIVE RANDOMIZED DOUBLE- BLINDED CLINICAL TRIAL","Inclusion Criteria:\n\n* Age between 5 and 14 years (preschool to early school age group at highest risk for EA).\n* ASA physical status I or II.\n* Scheduled for elective microscopic middle ear surgery under general anesthesia (e.g., tympanoplasty, myringoplasty).\n* Ability to comply with FLACC and PAED scoring during postoperative period.\n* Informed consent obtained from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Known neurological, developmental, or psychiatric disorders (e.g., autism, ADHD, seizure disorder).\n* Known hypersensitivity to amide local anesthetics (e.g., lidocaine, bupivacaine).\n* Skin infection, hematoma, or trauma at or near the proposed block site.\n* Non-elective (emergency) or combined surgeries.\n* Inability to assess pain or agitation due to hearing loss, or communication impairment.\n* Parental or legal guardian refusal to participate.",true,"5 Years","14 Years",{"count":134,"type":21},74,[54],"This study is designed to evaluate the effectiveness of ultrasound-guided greater auricular nerve block (GAN) on the reduction of emergence agitation (EA) occurrence and EA severity in children who are receiving general anesthesia for a microscopic middle ear operation.",[138,139,140,141,142,143],"Emergence Agitation","Emergence Delirium, Anesthesia","Emergence From Anesthesia","Emergence Delirium","Emergence Delirium in Pediatric Anesthesia","Emergence Agitation, Post Operative Behavioral Changes",[145,146,147],"emergence agitation","emergence delirium","EA","RECRUITING","2026-02-23",{"date":151,"type":34},"2026-02-27",{"date":153,"type":34},"2025-08-01",{"date":155,"type":21},"2026-04-01",{"name":40,"class":41},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":42},"100574663","the-effectiveness-of-ai-molar-mind-for-smoking-cessation-through-dental-health-evaluation-100574663","NCT06762210","the Effectiveness of AI Molar Mind for Smoking Cessation Through Dental Health Evaluation","the Effectiveness of AI Molar Mind for Smoking Cessation Through Dental Health Evaluation: Randomized Control Trial","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* smoke ≥5 cigarettes per day\n* motivated to quit smoking,\n* have access to a smartphone or computer\n\nExclusion Criteria:\n\n* Pregnant women\n* individuals with severe psychiatric conditions\n* those already using other smoking cessation therapies.","21 Years","65 Years",{"count":167,"type":21},300,[54],"Smoking cessation remains a significant public health challenge, with millions of individuals struggling to quit despite available interventions.",[171],"Smoking Cessation; Tobacco Dependence",[173,174],"Smoking cessation","oral health","2026-02-19",{"date":177,"type":34},"2026-02-20",{"date":179,"type":34},"2026-02-12",{"date":181,"type":21},"2026-09",{"name":40,"class":41},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":130,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":215,"locationsCount":42},"100624478","clinical-evaluation-of-microneedling-technique-with-topical-application-of-silymarin-on-gingival-hyperpigmentation-in-comparison-with-diode-laser-and-scalpel-methods-100624478","NCT07410156","Clinical Evaluation of Microneedling Technique With Topical Application of Silymarin on Gingival Hyperpigmentation in Comparison With Diode Laser and Scalpel Methods.","Clinical Evaluation of Microneedling Technique With Topical Application of Silymarin on Gingival Hyperpigmentation in Comparison With Diode Laser and Scalpel Methods. A Randomized Clinical Trial","Depigmentation","Inclusion Criteria:\n\n1. Patients will be free from any systemic diseases according to criteria of Modified Cornell Medical Index\n2. Patient with physiologic pigmentation\n3. Non smoker\n4. Patient agree to sign the written consent\n5. Both genders\n\nExclusion Criteria:\n\n1. Pregnant and lactating women\n2. Systemic conditions affect melanin production\n3. Medications induce pigmentation or enlargement\n4. Those with known allergies to silymarin.",{"count":192,"type":21},30,[54],"The present study will be carried to evaluate the efficacy of MN technique with topical Silymarin application in treating gingival hyperpigmentation in comparison with Laser and scalpel methods. This evaluation will be done clinically. The questions to be answered:\n\n* Is there a statistical difference between the microneedling (MN) technique with topical silymarin application, the scalpel technique, and the diode laser in providing clinical and aesthetic advantages in the treatment of gingival pigmentation?\n* What medical problems do participants have when using of Silymarin topically?\n\nParticipants will be:\n\nGroup 1 : The gingiva of the facial surfaces of the selected area will be de-epithelized by conventional method through blades no 15c.\n\nGroup 2 : The gingiva of the facial surfaces of the selected area will be de-epithelized by A Diode laser Device (serolaser).\n\nGroup 3 : The gingiva of the facial surfaces of the selected area will be treated by repetitive punctures with Dr.Pen ULTIMA - A6 needle tip. Silymarin is applied topically for ten minutes.",[196,197],"Gingival Pigmentation","Gingival Hyperpigmentaion",[199,200,201,202,203,204,205,206,207,208],"Gingival depigmentation","Microneedling","Laser","Silymarin","Scalpel","Surgical depigmentation","Micro-needling","MN","Topical application","gingival hyperpigmentation","2026-02-07",{"date":211,"type":34},"2026-02-13",{"date":213,"type":21},"2026-07-01",{"date":38,"type":21},{"name":40,"class":41},{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":17,"minAge":164,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":237,"leadSponsor":239,"locationsCount":42},"100623249","transforming-channel-osteotomy-into-tunnel-osteotomy-in-zygomatic-implant-preparation-100623249","NCT07394179","Transforming Channel Osteotomy Into Tunnel Osteotomy in Zygomatic Implant Preparation","Transforming Channel Shape Osteotomy Into Tunnel Shape Osteotomy for Zygomatic Implant. A Randomized Control Trial","Inclusion Criteria:\n\n1 -Patients older than 21 years. 2. Patients with severe alveolar bone atrophy in posterior maxilla (residual alveolar crest less than 5mm in height, in the area immediately distal to the canine pillar) 3. Patients with at least more than half of the zygomatic implant platform diameter inside the alveolar bone crest.\n\nExclusion Criteria:\n\n1 - Patients with systemic conditions contra-indicating general anesthesia. 2. Patients with conditions contraindicating implant placement (e.g.: radiation to the head and neck, intra-venous bisphosphonates, uncontrolled Diabetes mellitus).\n\n3\\. Patients with acute maxillary sinus infection or maxillary sinus cyst. 4. Restricted mouth opening (less than 3cm inter-arch distance anteriorly).",{"count":224,"type":21},24,[54],"The evolution of zygomatic implant techniques, from the original procedures to the Zygomatic Anatomy-Guided Approach (ZAGA), has significantly improved outcomes for patients with severe maxillary atrophy. Despite these advancements, challenges such as peri-implant tissue recession, sinus complications, and aesthetic concerns persist. Bone augmentation and soft tissue enhancement techniques, including sinus lifts, connective tissue grafts, and buccal fat pad utilization, have been employed to address these issues with varying degrees of success. However, the need for predictable and stable bone regeneration and soft tissue contouring remains critical for long-term implant success.\n\nThe following study aims to assess bone gain, soft tissue contour, and stability after using bone lamina shell, providing a potential solution to enhance peri-implant tissue integrity and optimize functional and aesthetic outcomes in zygomatic implant rehabilitation",[228],"Zygomatic Implants",[230,231,232],"Zygomatic implants","Grafting","Tunnel and channel","2026-02-01",{"date":235,"type":34},"2026-02-06",{"date":233,"type":21},{"date":238,"type":21},"2027-01-01",{"name":40,"class":41},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":263,"locationsCount":42},"100620240","the-effect-of-dexmedetomidine-versus-lidocaine-on-emergence-agitation-100620240","NCT07355049","The Effect of Dexmedetomidine Versus Lidocaine on Emergence Agitation.","The Effect of Intravenous Dexmedetomidine Versus Intravenous Lidocaine on the Emergence Agitation After Endoscopic Sinus Surgery. A Prospective, Randomized, Double-blind Controlled Trial.","Inclusion Criteria:\n\n* Age : 18-60\n* ASA Physical Status I or II\n* Elective endoscopic sinus surgery under general anesthesia .\n\nExclusion Criteria:\n\n* Refusal to participate\n* Mental retardation or inability to communicate\n* Allergy to anesthetics or study medications .\n* Chronic use of beta blockers .\n* significant hepatic, neurologic, cardiovascular or respiratory disease .\n* BMI\\>35 kg\u002Fm2","60 Years",{"count":20,"type":21},[54],"The effect of intravenous dexmedetomidine versus intravenous lidocaine on the emergence agitation after endoscopic sinus surgery.",[138],[253,254,255,256],"Emergence agitation","Intravenous dexmedetomidine","Endoscopic sinus surgery","Intravenous lidocaine","2026-01-20",{"date":259,"type":34},"2026-01-21",{"date":261,"type":21},"2025-12-21",{"date":233,"type":21},{"name":40,"class":41},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":4},"100618369","phase-3-lidocaine-patch-and-lower-third-molar-100618369","NCT07330726","Lidocaine Patch and Lower Third Molar","The Efficacy of a Transmucosal Lidocaine Patch on Postoperative Pain Following Mandibular Third Molar Extraction","Inclusion Criteria:\n\n* • Age ≥18ys\n\n  * no systemic disease\n  * impacted mandibular third molar class II position B on Pell- Gregory classification\n\nExclusion Criteria:\n\n* • history of metabolic or systemic diseases affecting bone or healing process,\n\n  * local infection,\n  * tobacco use,\n  * oral contraceptive,\n  * pregnancy and lactation\n  * patients who had taken analgesics or anti-inflammatories for 1 week prior to enrollment in the study.",{"count":272,"type":21},21,[274],"PHASE3","* Completed medical and dental history will take for all patients and the position of the impacted teeth will evaluate by panoramic films. Patients will fully inform about the treatment procedures, follow-up examinations and complications of surgical procedures.\n* Full thickness mucoperiosteal flap will be raised to expose sufficient bone on lateral and distal aspect of the impacted molar. Removal of bone will be done with stainless steel bur under Constant irrigation with normal saline while removing bone to prevent thermal necrosis.\n* When necessary, sectioning of crown and roots will be performed with a fissure bur. After tooth extraction, the alveolus will be inspected, curetted, and irrigated with 0.9% sterile saline solution.\n* Surgical removal of impacted mandibular third molar will be done,1% metformin gel or placebo gel in the socket following removal of the impacted third molar .\n* The mucoperiosteal flap will be repositioned and sutured with 3-0 black silk suture.\n* Control side : use transmucosal placebo patch\n* Study side: use transmucosal lidocaine patch Postoperative care\n* Postoperatively, the patients were instructed to apply ice bags 20 min\u002Fhour for the next 6 hours to the surgical side, eat soft cold diet by the aid of a straw and to avoid hot diet and fluid on the day of surgery.\n* Sutures were removed after 7 days postoperatively.\n* All the patients will be evaluated on the 1st, 3rd, and 7th postoperative days for pain, preoperative and postoperative mouth opening, and degree of postoperative swelling.",[277],"Impacted Third Molar Tooth","2025-12-28",{"date":280,"type":34},"2026-01-09",{"date":282,"type":21},"2026-01-01",{"date":284,"type":21},"2026-04-30",{"name":40,"class":41},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":304,"leadSponsor":306,"locationsCount":4},"100614265","analysis-of-the-outcomes-of-therapeutic-photorefractive-keratectomy-combined-with-prophylactic-accelerated-cross-linking-prk-plus-for-treatment-of-thin-suspicious-cornea-100614265","NCT07277348","Analysis of The Outcomes of Therapeutic Photorefractive Keratectomy Combined With Prophylactic Accelerated Cross-Linking (PRK-Plus), for Treatment of Thin Suspicious Cornea","Analysis of The Outcomes of Therapeutic Photorefractive Keratectomy Combined With Prophylactic Accelerated Cross-Linking (PRK-Plus), for Treatment of Thin Suspicious Cornea: Short-Term Pilot Study","Inclusion Criteria:\n\n1. CCT less than 490 microns\n2. K mean more than 46 and\u002For K max more than 47.\n3. Astigmatism cylinder \\>1.5 D.\n4. D value of Belin\u002FAmbrósio Module \\> 1.6\n5. inferior- superior asymmetry or bow-tie pattern with skewed radial axes on tangential maps and abnormal changes on (BAD).\n6. Asymmetry topography between 2 eyes, even if neither eye\"s topographic pattern is in itself decidedly abnormal.\n7. Any significant skewed radial axis with or without inferior steepening, or one diopter or more of inferior steepening in some areas but an I-S value of ,1.4,7.\n8. young patients with against-the-rule astigmatic patterns.\n9. a PTA value 40% if calculated.\n10. Abnormal Topographic Patterns\n11. K2 reading of corneal back surface less than \\[-7\\].\n12. D Value of CSTP \\> 2.5 in Belin\u002FAmbrósio curve\n13. We look at values within the central 5 mm circle; the map should be displayed in the BFTE float mode with an estimated area of 8 mm of diameter:\n\n    * Elevation values on the front surface values \\> +12 μ\n    * Elevation values on the back surface values \\>+15 μ.\n    * If there is any isolated island on either front or back surfaces (in the BFS float mode)\n\nExclusion Criteria:\n\n1. Eyes diagnosed with KC.\n2. CCT less than 450 microns","40 Years",{"count":295,"type":21},60,[54],"analyze the outcomes of therapeutic photorefractive keratectomy combined with prophylactic accelerated cross-linking (PRK-Plus), for treatment of thin suspicious cornea",[299],"Thin Suspicious Cornea","2025-12-09",{"date":302,"type":34},"2025-12-11",{"date":233,"type":21},{"date":305,"type":21},"2027-03-01",{"name":40,"class":41},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":314,"minAge":50,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":325,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":334,"leadSponsor":336,"locationsCount":42},"100611355","a-randomized-controlled-trial-evaluating-whether-pre-operative-trinase-reduces-post-operative-pain-in-patients-with-symptomatic-irreversible-pulpitis-compared-to-placebo-using-vas-scores-and-analgesic-intake-over-48-hours-100611355","NCT07239505","A Randomized Controlled Trial Evaluating Whether Pre-operative Trinase Reduces Post-operative Pain in Patients With Symptomatic Irreversible Pulpitis Compared to Placebo, Using VAS Scores and Analgesic Intake Over 48 Hours.","The Role Of Trinase In Reducing Post-Operative Pain For Patients With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Systemically healthy male patients (ASA I or II)\n* Aged 18 to 50 years\n* Presenting with symptomatic irreversible pulpitis in a restorable mandibular molar\n* Preoperative moderate to severe pain (VAS ≥45 mm)\n* Normal periapical tissue (no radiolucency, pocket depth ≤5 mm, mobility ≤ Grade I)\n\nExclusion Criteria:\n\nMedically compromised patients (ASA III or higher)\n\n* History of allergy or intolerance to Trinase or any of its components (trypsin, bromelain, rutin)\n* Vertical root fracture\n* External or internal root resorption\n* Periodontal pocket depth \\>5 mm\n* Tooth mobility Grade II or III\n* Presence of periapical lesion (radiolucency)\n* Female patients (to standardize pain perception and hormonal factors)","MALE","50 Years",{"count":317,"type":21},182,[54],"This study aims to determine whether Trinase, an enzyme-based anti-inflammatory medication, can reduce pain after root canal treatment in patients with symptomatic irreversible pulpitis. A total of 182 male patients aged 18 to 50 years who present with moderate to severe tooth pain will be randomly assigned to receive either a Trinase tablet or a placebo 30 minutes before treatment. All root canal procedures will be performed in a single visit using standard endodontic techniques.\n\nPain levels will be measured on a Visual Analogue Scale (VAS) before treatment and at 6, 12, 24, and 48 hours after treatment. Patients will also record the number of pain-relief tablets they take during the first 48 hours. The goal of the study is to see whether Trinase can lower post-operative pain and reduce the need for analgesic medication compared with placebo. This information may help improve pain management for patients undergoing root canal therapy.",[321,322,323,324],"Symptomatic Irreversible Pulpitis (SIP)","Postoperative Pain After Endodontic Treatment","Endodontic Disease","Dental Pain",[326,327,328,329],"Visual Analogue Scale (VAS)","Randomized Controlled Trial","Trinase","Postoperative Pain","2025-11-27",{"date":332,"type":34},"2025-12-01",{"date":153,"type":34},{"date":335,"type":21},"2025-12-15",{"name":40,"class":41},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":17,"minAge":315,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":42},"100556115","the-effect-of-the-combination-therapy-of-statin-and-sglt2i-in-the-treatment-of-ischemic-heart-disease-100556115","NCT06520891","\"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease\"","Inclusion Criteria:\n\n* we include patients established ischemic heart failure seen by a primary care provider to diagnose ischemic heart disease,\n* They assessed the use of statin with SGLT2i.\n\nExclusion Criteria:\n\n* We exclude patients with\n\n  1. liver dysfunction.\n  2. renal dysfunction.\n  3. fungal infection.\n  4. coagulation disorder.\n  5. Pts using drugs that interact with SGLT2i.\n  6. patients that will refuse to be enrolled in the Study or refuse to write informed consent.","80 Years",{"count":345,"type":21},90,"correlate the serum level of statin and SGLT2i when given as polytherapy with HPLC in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)",[348],"2 Drugs Are Statin and SGLT2i","2025-09-10",{"date":351,"type":34},"2025-09-11",{"date":353,"type":34},"2024-06-01",{"date":355,"type":21},"2025-12-30",{"name":40,"class":41},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":22,"phases":365,"briefSummary":366,"conditions":367,"keywords":370,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":377,"locationsCount":4},"100604319","phase-3-comparative-study-of-nutraceuticals-vs-conventional-prophylactic-therapy-in-the-management-of-migraine-100604319","NCT07147972","Comparative Study of Nutraceuticals vs. Conventional Prophylactic Therapy in the Management of Migraine","Inclusion Criteria:\n\n* Adults aged 18-60 years\n\n  * \\- Diagnosed with episodic migraine (ICHD-3 criteria)\n  * \\- ≥4 migraine attacks\u002Fmonth for the past 3 months\n  * \\- Willing to provide informed consent\n\nExclusion Criteria:\n\n* • - Chronic migraine (\\>15 headache days\u002Fmonth)\n\n  * \\- Use of other prophylactic treatments in past month\n  * \\- History of secondary headaches\n  * \\- Pregnancy or breastfeeding\n  * \\- Significant renal, hepatic, or cardiac disease",{"count":364,"type":21},100,[274],"Migraine is a common disabling neurological condition that significantly affects quality of life. While traditional prophylactic treatments (e.g., beta-blockers, antiepileptics) are effective, they may be associated with side effects leading to poor adherence. Recent evidence suggests that nutraceuticals like magnesium, riboflavin, and coenzyme Q10 may provide a safer alternative. This study aims to compare the efficacy and tolerability of these two approaches.",[368,369],"Migraine","Nutraceuticals",[368,369],"2025-08-27",{"date":373,"type":34},"2025-08-29",{"date":375,"type":21},"2025-08-20",{"date":233,"type":21},{"name":40,"class":41},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":17,"minAge":385,"maxAge":131,"enrollmentInfo":386,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":42},"100581901","effect-of-furlow-palatoplasty-with-buccal-myomucosal-flap-on-the-speech-development-100581901","NCT06856330","Effect of Furlow Palatoplasty With Buccal Myomucosal Flap on the Speech Development","Efficacy of Two Flap Palatoplasty (TFP) Versus Furlow With Buccinator Flap (FPBF) During Primary Palatoplasty on the Speech Development","Inclusion Criteria:\n\n* 3-5 years old childreen with previous treated complete cleft lip and palate, nonsyndromic.\n* lip and palate repair performed by one craniofacial surgeon\n\nExclusion Criteria:\n\n* Patients with syndromic cleft lip.\n* Redu cases\n* Bilateral cleft lip\n* Patient older 5years or younger 3 years.\n* Associated Cardiac anomalies.\n* Any systemic condition","3 Years",{"count":192,"type":21},"About 20 patient will be collected according to the eligibility criteria and grouped into Group I : 10 patients were treated with furlow with buccinators flap Group II : 10 patients were treated with 2 flap palatoplasty All patients will be examined by an expert Phoniatrician by Recording of speech samples in Arabic language for the children in a soundproof room including repeated syllables, sentences with high-pressure sounds and counting from 1 to 10. The records will be analyzed to assess the degree of hypernasality, speech intelligibility and compensatory speech errors",[389],"Cleft Palate","2025-07-24",{"date":392,"type":34},"2025-07-28",{"date":394,"type":34},"2025-03-25",{"date":396,"type":21},"2025-07-25",{"name":40,"class":41},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":315,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":4},"100598325","phase-1-efficacy-of-microneedling-with-vitamin-c-in-performing-gingival-depigmentation-100598325","NCT07070024","Efficacy of Microneedling With Vitamin C in Performing Gingival Depigmentation","Efficacy of Microneedling With Vitamin C in Performing Gingival Depigmentation Compared With Conventional Scalpel and Diode Laser: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients with bilateral, diffuse and symmetric physiologic gingival pigmentation in the labial maxillary or mandible gingiva.\n2. Patients free from any systemic diseases according to criteria of Modified Cornell Medical Index. (Abramson J et al., 1966)\n3. Periodontally healthy patient.\n4. Patients with age between 18 and 50 years\n\nExclusion Criteria:\n\n1. Smokers.\n2. Drugs intake \"mainly those associated with gingival pigmentation\".\n3. Pregnant and lactating women.\n4. Patients with thin gingival phenotype \"with scalpel group\".\n5. Gingival pigmentation associated with occupational hazards.\n6. Individuals undergoing chemotherapy",{"count":192,"type":21},[407,111],"PHASE1","The present study will be carried to clinically evaluate the efficacy of microneedling with vitamin C in performing gingival depigmentation in comparison with conventional scalpel and diode laser.",[196],"2025-07-15",{"date":412,"type":34},"2025-07-17",{"date":414,"type":21},"2025-07",{"date":416,"type":21},"2026-12",{"name":40,"class":41},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":247,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":436,"leadSponsor":438,"locationsCount":42},"100599086","alveolar-ridge-augmentation-using-minimally-invasive-subperiosteal-tunneling-with-xenogenic-bone-graft-and-prf-100599086","NCT07079917","Alveolar Ridge Augmentation Using Minimally Invasive Subperiosteal Tunneling With Xenogenic Bone Graft and PRF","Alveolar Ridge Augmentation Using Minimally Invasive Subperiosteal Tunneling With Xenogenic Bone Graft and Platelet-Rich Fibrin: Randomized Controlled Trial","MISTT","Inclusion Criteria:\n\n* Adults over 18 years old seeking an implant-supported restoration with deficient horizontal posterior maxillary alveolar ridge, at area of one or two missed teeth of less than 5 mm buccolingual width.\n* Minimum vertical height of 8 mm.\n* Gingival tissue of healthy adequate keratinization, more than 2mm.\n\nExclusion Criteria:\n\n* The presence of uncontrolled diabetes or any other systemic condition which may complicate the surgical procedure or interfere with bone healing\n* Radiotherapy to the head and neck region\n* Chemotherapy within the last 12 months\n* Uncontrolled periodontitis\n* Smoking\n* Bisphosphonate therapy\n* Pregnancy\n* Presence of periapical infection or lesion",{"count":427,"type":21},16,[54],"surgical horizontal augmentation for maxillary alveolar ridge using minimally invasive subperiosteal tunneling in comparison to conventional surgical technique",[431],"Alveolar Bone Loss","2025-07-14",{"date":434,"type":34},"2025-07-23",{"date":153,"type":21},{"date":437,"type":21},"2026-06-21",{"name":40,"class":41},{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":130,"sex":17,"minAge":446,"maxAge":132,"enrollmentInfo":447,"targetDuration":4,"studyType":22,"phases":449,"briefSummary":450,"conditions":451,"keywords":454,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":460,"leadSponsor":461,"locationsCount":42},"100596422","effect-of-co-enzyme-q10-on-the-bone-volume-of-alveolar-cleft-reconstruction-100596422","NCT07045246","Effect of Co-enzyme Q10 on the Bone Volume of Alveolar Cleft Reconstruction","The Evaluation of the Effect of Co-enzyme Q10 on the Bone Volume of Alveolar Cleft Reconstruction (Randomized Clinical Trial)","Inclusion Criteria:\n\n* age ranged between 10-14 years, with good oral hygiene and general good health\n\nExclusion Criteria:\n\n* patients with syndromes associated with an alveolar cleft, local pathosis at the maxilla that may interfere with surgery, previous grafting attempts, or cleft palate fistulae","10 Years",{"count":448,"type":21},12,[54],"Evaluate the effect of Co-enzyme Q10 on the bone volume in unilateral alveolar cleft repair",[452,453],"Coenzyme Q10","Alveolar Cleft Grafting",[455],"alveolar cleft reconstruction","2025-07-03",{"date":458,"type":34},"2025-07-09",{"date":410,"type":21},{"date":155,"type":21},{"name":40,"class":41},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":130,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":478,"locationsCount":4},"100596246","evaluation-of-customized-zirconia-membrane-in-direct-sinus-lifting-with-simultaneous-implant-placement-randomized-control-trial-100596246","NCT07042958","Evaluation of Customized Zirconia Membrane in Direct Sinus Lifting With Simultaneous Implant Placement: (Randomized Control Trial)","Patient will be selected according to certain inclusion and exclusion criteria:\n\n1\\. Inclusion criteria Patient with Atrophic posterior maxilla and remaining bone height less than 6 mm.\n\nI. ASA physical status I and II. II. Patient with healthy maxillary sinus free from any pathology. III. The edentulous ridges are covered with optimal thickness of Mucoperiosteum with no signs of inflammation, ulceration or scar tissue.\n\nIV. Occlusion showed sufficient inter arch space for future prosthesis.\n\nExclusion Criteria:\n\nGeneral contraindications to implant surgery. I. Untreated gingivitis, periodontitis. II. Patient with maxillary sinusitis. III. Smoker patient. IV. Patient with parafunctional habits. V. Subjected to irradiation in the head and neck area less than 1 year before implantation.\n\nVI. Pregnant or nursing.",{"count":224,"type":21},[54],"Modern dental implantology offers solutions for patients with edentulism in the maxillary arch, where sinus pneumatization and alveolar ridge atrophy are common. This requires sinus floor elevation and bone grafting for implant placement. Techniques like the lateral window approach and osteotome-mediated sinus floor elevation aim to achieve the necessary vertical bone height for implants. Autogenous bone grafts have been the gold standard but have limitations like donor site morbidity and graft volume loss, leading to the exploration of alternatives. Membranes, such as resorbable collagen or titanium-reinforced materials, are commonly used in these procedures but have limitations related to customization, cost, and failure rates.Recent studies have suggested that placing implants directly into the sinus without grafting material can stimulate bone formation, leveraging blood clots to activate bone-forming cells. Zirconia, a ceramic material known for its bioinertness and mechanical strength, is being explored for its potential in sinus lift procedures. Customized 3D zirconia membranes may offer a solution to enhance bone formation and soft tissue integration during sinus lifts.This study aims to evaluate the effect of using customized zirconia membranes in sinus lift procedures with simultaneous implant placement, comparing bone height outcomes with conventional sinus lifts without membranes",[57],"2025-06-20",{"date":474,"type":34},"2025-06-29",{"date":476,"type":21},"2025-07-01",{"date":213,"type":21},{"name":40,"class":41},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":164,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":492,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":42},"100594237","guided-pterygoid-implant-100594237","NCT07016828","Guided Pterygoid Implant","Comparing Accuracy of Pterygoid Implants Placement Using Computer-guided Surgical Templates Versus Free Hand Technique","Inclusion Criteria:\n\n1. Patients with severe posterior maxillary atrophy (Class V-VI Cawood \\& Howell classification) requiring pterygoid implant placement.\n2. Patients with severe alveolar bone atrophy in posterior maxilla (Residual alveolar bone height \\\u003C4mm in posterior maxilla precluding conventional implant placement).\n3. Adequate interarch space ≥7mm for prosthetic rehabilitation.\n4. Presence of pneumatized maxillary sinus with insufficient bone for sinus augmentation.\n5. Patients aged 21-75 years with completed craniofacial growth.\n\nExclusion Criteria:\n\n1. Patients with systemic conditions contra-indicating general anesthesia.\n2. Patients with conditions contraindicating implant placement (e.g.:\n\n   radiation to the head and neck, intra-venous bisphosphonates, uncontrolled Diabetes mellitus).\n3. Patients with acute maxillary sinus infection or maxillary sinus cyst.\n4. Restricted mouth opening (less than 3cm inter-arch distance anteriorly).","75 Years",{"count":448,"type":21},[54],"Introduction \\& Background Alveolar ridge resorption after tooth extraction leads to significant bone loss, complicating prosthetic rehabilitation. Traditional bone grafting methods, though effective, involve long healing times and risks. Pterygoid implants offer a graft-free alternative by engaging dense bone structures like the pterygoid process. However, their placement is technically challenging due to limited visibility and proximity to critical structures. Computer-guided surgery may improve accuracy and reduce complications compared to freehand techniques.\n\nResearch Question Does computer-guided surgery enhance the accuracy of pterygoid implant placement in atrophic maxillae compared to freehand techniques? Aim To compare the accuracy of computer-generated 3D surgical guides versus freehand placement of pterygoid implants.\n\nHypothesis\n\n* H0: No difference in accuracy between techniques.\n* Hₐ: there is difference between two techniques Study Design A prospective randomized controlled trial (1:1 allocation) with 12 implants (6 per group(.\n\nPatient Selection Inclusion Criteria: Severe posterior maxillary atrophy (Cawood \\& Howell V-VI), residual bone height \\\u003C4mm, age 21-75.\n\nExclusion Criteria: Contraindications for surgery, uncontrolled systemic diseases, or acute sinus infections.\n\nMethods\n\n* Group A: Implants placed using CBCT-based 3D surgical guides.\n* Group B: Freehand placement based on anatomical landmarks.\n* Primary Outcome: Implant position accuracy (postoperative CBCT vs. virtual plan(.\n* Secondary Outcomes: Surgical time, complications, and stability. Surgical Procedure\n* Osteotomy: Angled drilling (45-60°) into the pterygoid process.\n* Implant Placement: Torque ≥30 Ncm for primary stability.\n* Postoperative Care: Antibiotics, analgesics, and follow-up CBCT at one week. Statistical Analysis Data analyzed using SPSS, with G\\*Power determining sample size (85% power, α = 0.05(.\n\nEthical Considerations Approved by institutional review boards, with informed consent and confidentiality maintained.",[491],"Atrophy of the Posterior Maxilla",[493,494,495],"guided surgery","pterygoid implant","atrophic maxilla","2025-06-11",{"date":498,"type":34},"2025-06-12",{"date":500,"type":21},"2025-07-30",{"date":502,"type":21},"2026-06-30",{"name":40,"class":41},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":130,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":22,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":4},"100591637","sticky-bone-vs-xenograft-with-cross-linked-hyaluronic-acid-in-socket-preservation-100591637","NCT06983015","Sticky Bone vs Xenograft With Cross-linked Hyaluronic Acid in Socket Preservation","The Effect of Sticky Bone vs Cross-linked Hyaluronic Acid With Xenograft in Socket Preservation: Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18 years old.\n* Patient with hopeless maxillary anteriors and premolar with cl ii socket that needs extraction and delayed implant placement.\n\nExclusion Criteria:\n\n* Acute abscesses or active infections localized in the proximity of the surgical field.\n* Presence of heavy metallic artefacts that can distort CBCT scans\n* Bad oral hygiene and non-compliance.\n* Systemic diseases interfering with bone healing.\n* Active and progressive periodontal disease\n* Smoking, alcoholism and drug abuse\n* Pregnant and lactating women",{"count":81,"type":21},[54],"The present study aimed to evaluate clinical and radiographic outcomes of sticky bone in comparison to crosslinked hyaluronic acid mixed with xenograft in alveolar ridge preservation.",[515],"Socket Preservation",[62,517],"xenograft with cross-linked hyaluronic acid","2025-05-23",{"date":520,"type":34},"2025-05-29",{"date":522,"type":21},"2025-06",{"date":524,"type":21},"2026-07",{"name":40,"class":41},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":22,"phases":535,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":545,"locationsCount":4},"100591433","phase-1-hyaluronidase-enzymes-and-local-anesthesia-100591433","NCT06980363","Hyaluronidase Enzymes and Local Anesthesia","Efficacy of Articaine Plus Hyaluronidase Enzymes Infiltration Versus Traditional Inferior Alveolar Nerve Block for the Extraction of Mandibular Molars","Inclusion Criteria:\n\n* Medically stable patients\n* Seeking for non surgical extraction of mandibular molar tooth\n\nExclusion Criteria:\n\n* history of metabolic or systemic diseases affecting bone or healing process,\n\n  * local infection\n  * Grade III mobility\n  * Neurological disorder\n  * an analgesic use within 24 hours before anaesthesia administration",{"count":534,"type":21},20,[407],"* For both groups, local anaesthesia will be administered by one single surgeon and the extraction will be performed by another single surgeon across all subjects. The surgeon performing the extraction will be blinded with regard to the local anaesthesia technique used in this study\n* A buccal infiltration injection of 1.5 ml of 4% articaine with 1:100,000 adrenaline (Septocaine, Septodont, New Castle, Del.) plus 1.5 ml of hyaluronidase enzyme (7.5IU\u002F1ml) will be used in the study group while use 4% articaine with 1:100,000 adrenaline (Septocaine, Septodont, New Castle, Del.)only in traditional inferior alveolar nerve block in the control group\n* In study and control groups, VAS (visual analogue scale=is an unmarked, continuous, horizontal,100-mm line, anchored by the end points of \"no pain\" on the left and \"worst pain\" on the right ) will be used to evaluate the pain levels of the patients associated with the injection and during extraction",[538],"Local Infiltration","2025-05-19",{"date":541,"type":34},"2025-05-20",{"date":543,"type":21},"2025-06-01",{"date":371,"type":21},{"name":40,"class":41},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":247,"enrollmentInfo":553,"targetDuration":4,"studyType":22,"phases":554,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":564,"leadSponsor":566,"locationsCount":42},"100592196","phase-2-micro-needling-technique-using-ozonated-olive-oil-in-periodontal-diseases-100592196","NCT06990282","Micro-Needling Technique Using Ozonated Olive Oil in Periodontal Diseases","The Effectiveness of Micro-Needling Technique Using Ozonated Olive Oil on The Treatment of Biofilm Induced Gingivitis & Periodontitis in Comparison to Professional Mechanical Plaque Removal: A Randomized Control Trial.","Inclusion Criteria:\n\n* Age 18-60 years old\n* Male and female medically free participants\n* Patients suffering from biofilm induced gingivitis or periodontitis\n\nExclusion Criteria:\n\n* Smoking and tobacco related habits\n* Non-biofilm induced gingival diseases\n* Necrotizing periodontal diseases\n* periodontitis as a manifestation of systemic disease\n* Third molar tooth",{"count":192,"type":21},[111],"The research idea is based on using micro-acupuncture therapy with ozone-treated olive oil to improve the condition of patients suffering from gingivitis and periodontitis and comparing it to the scientifically proven conventional treatment. This is a randomized controlled study, and this idea was chosen from the current general trend in medicine, particularly in dentistry, to use natural sources for treatment due to fewer side effects compared to the chemicals used.",[557,558,559],"Periodontal Diseases","Periodontitis and Treatment Need","Gingivitis","2025-05-18",{"date":562,"type":34},"2025-05-25",{"date":476,"type":21},{"date":565,"type":21},"2026-03",{"name":40,"class":41},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":582,"leadSponsor":583,"locationsCount":4},"100591694","evaluation-of-erythropoietin-therapy-in-patients-with-end-stage-kidney-disease-on-regular-hemodialysis-hemoglobin-outcomes-and-metabolic-syndrome-as-a-risk-factor-for-erythropoietin-resistance--100591694","NCT06983756","\" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance \"","Inclusion Criteria:\n\n* Patients (and replacements) will be randomly selected by a raffle.\n* All participants should be 18 years of age or older and agree to participate in the study after due clarification.\n* Patients with end stage kidney disease (ESKD) on regular hemodialysis for more than 3 months.\n\nExclusion Criteria:\n\n* \\- Patients with neoplasm, severe cardiovascular, cerebrovascular and liver diseases.\n* Females with polycystic ovarian syndrome, those on hormonal replacement therapy and pregnant women.\n* Patients with infection or autoimmune diseases.",{"count":574,"type":21},66,"The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).",[577],"Erythropoietin Resistant Anemia (EPO Resistant Anemia)","2025-05-14",{"date":580,"type":34},"2025-05-21",{"date":543,"type":21},{"date":282,"type":21},{"name":40,"class":41},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":22,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":600,"leadSponsor":602,"locationsCount":4},"100591083","phase-2-magnesium-sulfate-and-trigger-points-100591083","NCT06975813","Magnesium Sulfate and Trigger Points","Efficacy of Isolated Masseter Versus Masseter- Sternocleidomastoid Trigger Points Injection by Magnesium Sulfate for Myofacial Pain","Inclusion Criteria:\n\n* definite diagnosis of myofascial pain\n* presence of one or more unilateral or bilateral trigger points in the masseter muscle and sternocleidomastoid muscle;\n* no history of any invasive procedures of the related masseter muscle.\n\nExclusion Criteria:\n\n* any painful conditions (other than myofascial trigger points) affecting the orofacial region\n* any systemic diseases that could masticatory function (e.g., rheumatoid arthritis and epilepsy);\n* pregnancy and lactation",{"count":192,"type":21},[111],"The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter \\&sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever",[595],"Myofascial Pain Syndrome","2025-05-09",{"date":598,"type":34},"2025-05-16",{"date":543,"type":21},{"date":601,"type":21},"2026-01-27",{"name":40,"class":41},""]